Prominent and fast response to eculizumab in myasthenic crisis: the potential as rescue therapy in refractory myasthenia gravis
Neurological Sciences · 2025-07 · 46 (7) · 3299-3302
DOI: 10.1007/s10072-025-08128-4 ↗Kurz gefasst
Fallbericht in der Zeitschrift Neurological Sciences, online erschienen am 20.03.2025. Verfasst von Christian Messina und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, and Advanced Technologies, G.F. Ingrassia, Azienda Ospedaliera Universitaria G. Rodolico-San Marco, Univ…. Hauptthemen laut MEDLINE: Myasthenia Gravis, Antibodies, Monoclonal, Humanized, Complement Inactivating Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease caused by antibodies against the postsynaptic membrane at the neuromuscular junction, leading to muscle weakness, fatigue, and respiratory failure in severe cases. Myasthenic crisis (MC) is a life-threatening condition which requires hospitalization and treatments with intravenous immunoglobulin, plasma exchange and high dose steroids. We report a case of a patient with refractory MC and anti-AChR antibodies positivity who started Eculizumab as rescue therapy, leading to a complete resolution of the acute neuromuscular condition. CASE PRESENTATION: A 72-year-old man presented with bilateral ptosis, severe weakness in all limbs, dysphonia, dysphagia and dyspnea. He was diagnosed with MG with anti-AChR positivity and refractory MC. He was unresponsive to classical rescue therapy, so he underwent Eculizumab administration which resulted in a notable improvement in symptoms. DISCUSSION: Eculizumab, a humanized monoclonal antibody that inhibits complement activation, is now approved as treatment for refractory generalized MG with anti-AChR antibodies. The use of eculizumab in refractory MC is still under investigation; however, this case report suggests that it could be a promising treatment option for patients with severe acute clinical condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences, and Advanced Technologies, G.F. Ingrassia, Azienda Ospedaliera Universitaria G. Rodolico-San Marco, University of Catania, Catania, Italy. chry.messina@gmail.com.
- Regional Center for Diagnosis and Treatment of Neuromuscular Disease, Department of Biomedicine, Neuroscience and Advanced Diagnostic (BIND), University of Palermo, Palermo, Italy. chry.messina@gmail.com.
- Division of Respiratory Medicine, Department PROMISE, Giaccone University Hospital, University of Palermo, Palermo, Italy.
- Regional Center for Diagnosis and Treatment of Neuromuscular Disease, Department of Biomedicine, Neuroscience and Advanced Diagnostic (BIND), University of Palermo, Palermo, Italy.
- National Research Council, Institute of Biomedical Research and Innovation (IRIB-CNR), Palermo, Italy.
Zitieren
APA
Messina, C., Basile, L., Crescimanno, G., Battaglia, S., Scichilone, N., Brighina, F., & Di Stefano, V. (2025). Prominent and fast response to eculizumab in myasthenic crisis: the potential as rescue therapy in refractory myasthenia gravis. Neurological Sciences, 46(7), 3299-3302. https://doi.org/10.1007/s10072-025-08128-4
Vancouver
Messina C, Basile L, Crescimanno G, Battaglia S, Scichilone N, Brighina F, et al. Prominent and fast response to eculizumab in myasthenic crisis: the potential as rescue therapy in refractory myasthenia gravis. Neurological Sciences. 2025;46(7):3299-3302. doi:10.1007/s10072-025-08128-4
BibTeX
@article{Messina2025,
author = {Messina, Christian and Basile, Laura and Crescimanno, Grazia and Battaglia, Salvatore and Scichilone, Nicola and Brighina, Filippo and Di Stefano, Vincenzo},
title = {Prominent and fast response to eculizumab in myasthenic crisis: the potential as rescue therapy in refractory myasthenia gravis},
journal = {Neurological Sciences},
year = {2025},
volume = {46},
number = {7},
pages = {3299--3302},
doi = {10.1007/s10072-025-08128-4}
}
EUVIMED